Padilla Ureña, Yirlany; Cascante Gutiérrez, Allison; Arriola Gutiérrez, Jordan G

Language: Spanish
References: 17
Page:
PDF size: 287.48 Kb.

ABSTRACT

Fever of unknown origin is a great challenge for physicians since its approach involves a wide range of differential diagnoses. The main causes are infectious, neoplastic and rheumatological, with infectious causes being the most frequent. Within rheumatological causes, JIA represents the main cause of FUO of rheumatological origin. A rare but highly fatal variant is systemic juvenile idiopathic arthritis.
Pathophysiologically, sJIA is characterized by activation of cells of the innate immune system, with the role of the adaptive immune response being limited in this disease. Within the clinical spectrum fever, arthritis, skin rash, and lymphadenopathy are the most common manifestations at diagnosis. As expected, sJIA is a diagnosis of exclusion and the key finding is the combination of fever with a daily pattern and arthritis; however, these are not highly specific signs and will require an extensive exercise in differential diagnoses.
Regarding treatment, the understanding of the pathophysiology of the disease has allowed the development of targeted therapies that, according to the evidence and current practice, reduce the morbidity and mortality of the disease.

REFERENCES

1. Santana LF, Rodrigues Mde, Silva MP, Brito RJ, Nicacio JM, Duarte RM, et al. Fever of unknown origin – a literature review. Revista da Associação Médica Brasileira. 2019;65(8):1109–15.

2. Chien Y-L, Huang F-L, Huang C-M, Chen P-Y. Clinical approach to fever of unknown origin in children. Journal of Microbiology, Immunology and Infection. 2017;50(6):893–8.

3. Jung J-Y, Kim J-W, Suh C-H, Kim H-A. Roles of interactions between toll-like recep-tors and their endogenous ligands in the pathogenesis of systemic juvenile idiopathic arthritis and adult-onset still’s disease. Frontiers in Immunology. 2020;11.

4. Pardeo M, Bracaglia C, De Benedetti F. Systemic juvenile idiopathic arthritis: New in-sights into pathogenesis and cytokine directed therapies. Best Practice & Re-search Clinical Rheumatology. 2017;31(4):505–16.

5. Lee JJY, Schneider R. Systemic juvenile idiopathic arthritis. Pediatric Clinics of North America. 2018;65(4):691–709.

6. Kimura Y. Systemic juvenile idiopathic artrhritis: Clinical manifestations and diagnosis. In: UpToDate, Klein-Gitelman M (Ed), UpToDate, Waltham, MA. (Accesado el 06 de junio, 2022)

7. Kessel C, Hedrich CM, Foell D. Innately adaptive or truly autoimmune: Is there some-thing unique about systemic juvenile idiopathic arthritis? Arthritis & Rheumatology. 2020;72(2):210–9.

8. Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: From aetiopathogenesis to therapeutic approaches. Pediatric Rheumatology. 2021;19(1).

9. Sağ E, Uzunoğlu B, Bal F, Sönmez HE, Demir S, Bilginer Y, et al. Systemic onset ju-venile idiopathic arthritis: A single center experience. The Turkish Journal of Pediat-rics. 2019;61(6):852.

10. Kimura Y. Systemic juvenile idiopathic artrhritis: Course, prognosis and complications. In: UpToDate, Klein-Gitelman M (Ed), UpToDate, Waltham, MA. (Accesado el 06 de junio, 2022)

11. Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles‐Han ST, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: Therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis & Rheumatology. 2022;74(4):553–69.

12. Yasin S, Schulert GS. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: Update on pathogenesis and treatment. Current Opinion in Rheumatolo-gy. 2018;30(5):514–20.

13. Tomaras S, Goetzke CC, Kallinich T, Feist E. Adult-onset still’s disease: Clinical as-pects and therapeutic approach. Journal of Clinical Medicine. 2021;10(4):733.

14. Kimura Y. Systemic juvenile idiopathic artrhritis: Treatment. In: UpToDate, Klein-Gitelman M (Ed), UpToDate, Waltham, MA. (Accesado el 06 de junio, 2022)

15. Onel K, Rumsey DG, Shenoi S. Juvenile idiopathic arthritis treatment updates. Rheu-matic Disease Clinics of North America. 2021;47(4):545–63.

16. Bielak M, Husmann E, Weyandt N, Haas J-P, Hügle B, Horneff G, et al. IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German aid-registry). Pediatric Rheumatology. 2018;16(1).

17. Mejbri M, Theodoropoulou K, Hofer M, Cimaz R. Interleukin-1 blockade in systemic juvenile idiopathic arthritis. Pediatric Drugs. 2020;22(3):251–62.